Page last updated: 2024-11-10

2'-hydroxyformononetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-hydroxyformononetin : A member of the class of 4'-methoxyisoflavones that is formononetin with a hydroxy group at the 2'position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280551
CHEMBL ID253514
CHEBI ID17678
SCHEMBL ID72611

Synonyms (19)

Synonym
xenognosin b
CHEBI:17678 ,
7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-4h-chromen-4-one
C02920 ,
1890-99-9
2'-hydroxyformononetin
2'-hydroformononetin
2-HYDROXYFORMONONETIN ,
CHEMBL253514
LMPK12050081
7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)chromen-4-one
SCHEMBL72611
XKHHKXCBFHUOHM-UHFFFAOYSA-N
7-hydroxy-3-(2-hydroxy-4-methoxy-phenyl)-chromen-4-one
DTXSID30415062
4h-1-benzopyran-4-one, 7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-
7,2'-dihydroxy-4'-methoxyisoflavone
2',7-dihydroxy-4'-methoxyisoflavone
Q23055344
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
7-hydroxyisoflavonesA hydroxyisoflavone compound having a hydroxy group at the 7-position.
4'-methoxyisoflavonesAny methoxyisoflavone which has a methoxy group at the 4-position of the phenyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
superpathway of pterocarpan biosynthesis (via formononetin)031
(-)-medicarpin biosynthesis010
superpathway of formononetin derivative biosynthesis031
(-)-medicarpin biosynthesis210
superpathway of pterocarpan biosynthesis (via formononetin)334
superpathway of formononetin derivative biosynthesis234
Medicarpin biosynthesis012

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1453621Inhibition of LPS-induced NF-kappaB transcription (unknown origin) expressed in human SW480 cells at 10 uM by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID404183Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1453623Inhibition of recombinant human PTP1B using p-nitrophenyl phosphate as substrate at 10 uM after 30 mins relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID404179Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID367738Induction of DR5 promoter activity in SacI gene expressing human DLD1 cells at 17.5 uM after 24 hrs by luminescence assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Death receptor 5 targeting activity-guided isolation of isoflavones from Millettia brandisiana and Ardisia colorata and evaluation of ability to induce TRAIL-mediated apoptosis.
AID1453625Inhibition of mushroom tyrosinase at 10 uM using L-tyrosine as substrate incubated for 15 mins followed by substrate addition relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID1453615Growth inhibition of human SW480 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID404181Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1453614Growth inhibition of human MCF7 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID404180Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID404184Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID404182Cytotoxicity against human A549 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Cytotoxic constituents from Brazilian red propolis and their structure-activity relationship.
AID1463920Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1453616Growth inhibition of human HepG2 cells at 10 uM after 24 hrs by MTS assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
AID313354Cytotoxicity against human PANC1 cells in nutrient deprived medium after 24 hrs2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition.
AID1453619Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM after 24 hrs by Griess reagent based assay relative to control2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]